Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
01 Junho 2023 - 9:00AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Antony Mattessich,
President and Chief Executive Officer of Ocular Therapeutix, will
participate in a fireside chat at the Jefferies Global Healthcare
Conference on Thursday, June 8, 2023 at 12:30 PM EDT at the
Marriott Marquis in New York, NY.
In addition to the fireside chat, the management team will host
investor meetings at the conference. Investors participating in the
conference who are interested in meeting with Ocular Therapeutix
management should contact their Jefferies representative.
A live webcast of the fireside chat can be accessed by visiting
the Investors section of the Company’s website at
investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused
on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and diabetic retinopathy;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-DED (dexamethasone intracanalicular
insert) for the short-term treatment of the signs and symptoms of
dry eye disease; and OTX-CSI (cyclosporine intracanalicular insert)
for the chronic treatment of dry eye disease, both of which have
completed Phase 2 clinical trials.
InvestorsOcular TherapeutixDonald NotmanChief
Financial Officerdnotman@ocutx.com
or
ICR Westwicke Chris BrinzeyManaging
Directorchris.brinzey@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024